Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study

•Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing titer•Anti-Spike IgG were not significantly lower in subjects with secondary infections•Secondary infection is usually asymptomatic or mildly sympto...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of infectious diseases Vol. 109; pp. 199 - 202
Main Authors Rovida, Francesca, Cassaniti, Irene, Percivalle, Elena, Sarasini, Antonella, Paolucci, Stefania, Klersy, Catherine, Cutti, Sara, Novelli, Viola, Marena, Carlo, Luzzaro, Francesco, De Vito, Giovanni, Schiavo, Roberta, Lo Cascio, Giuliana, Lilleri, Daniele, Baldanti, Fausto
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.08.2021
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing titer•Anti-Spike IgG were not significantly lower in subjects with secondary infections•Secondary infection is usually asymptomatic or mildly symptomatic•Vaccination of SARS-CoV-2-seronegative subjects might be prioritized The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated. The frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection. During the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78). Immunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized.
AbstractList Objective: The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated. Methods: The frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection. Results: During the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78). Conclusions: Immunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized.
OBJECTIVEThe protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated. METHODSThe frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection. RESULTSDuring the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78). CONCLUSIONSImmunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized.
• Immunity from natural SARS-CoV-2 infection is protective in healthcare workers • Secondary infection is associated with low or absent serum neutralizing titer • Anti-Spike IgG were not significantly lower in subjects with secondary infections • Secondary infection is usually asymptomatic or mildly symptomatic • Vaccination of SARS-CoV-2-seronegative subjects might be prioritized
•Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing titer•Anti-Spike IgG were not significantly lower in subjects with secondary infections•Secondary infection is usually asymptomatic or mildly symptomatic•Vaccination of SARS-CoV-2-seronegative subjects might be prioritized The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated. The frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection. During the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78). Immunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized.
Author Klersy, Catherine
Baldanti, Fausto
Percivalle, Elena
Marena, Carlo
Luzzaro, Francesco
Lo Cascio, Giuliana
Cassaniti, Irene
Cutti, Sara
Paolucci, Stefania
Novelli, Viola
De Vito, Giovanni
Lilleri, Daniele
Schiavo, Roberta
Sarasini, Antonella
Rovida, Francesca
Author_xml – sequence: 1
  givenname: Francesca
  surname: Rovida
  fullname: Rovida, Francesca
  organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 2
  givenname: Irene
  surname: Cassaniti
  fullname: Cassaniti, Irene
  organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 3
  givenname: Elena
  surname: Percivalle
  fullname: Percivalle, Elena
  organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 4
  givenname: Antonella
  surname: Sarasini
  fullname: Sarasini, Antonella
  organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 5
  givenname: Stefania
  surname: Paolucci
  fullname: Paolucci, Stefania
  organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 6
  givenname: Catherine
  surname: Klersy
  fullname: Klersy, Catherine
  organization: Biometry and Clinical Epidemiology Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 7
  givenname: Sara
  surname: Cutti
  fullname: Cutti, Sara
  organization: Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 8
  givenname: Viola
  surname: Novelli
  fullname: Novelli, Viola
  organization: Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 9
  givenname: Carlo
  surname: Marena
  fullname: Marena, Carlo
  organization: Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 10
  givenname: Francesco
  surname: Luzzaro
  fullname: Luzzaro, Francesco
  organization: Clinical Microbiology and Virology Unit, Lecco A. Manzoni Hospital, Lecco, Italy
– sequence: 11
  givenname: Giovanni
  surname: De Vito
  fullname: De Vito, Giovanni
  organization: Occupational Medicine Unit, A. Manzoni Hospital, Lecco, School of Medicine & Surgery, Milano Bicocca University
– sequence: 12
  givenname: Roberta
  surname: Schiavo
  fullname: Schiavo, Roberta
  organization: Microbiology Unit, Clinical Pathology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy
– sequence: 13
  givenname: Giuliana
  surname: Lo Cascio
  fullname: Lo Cascio, Giuliana
  organization: Microbiology Unit, Clinical Pathology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy
– sequence: 14
  givenname: Daniele
  surname: Lilleri
  fullname: Lilleri, Daniele
  email: d.lilleri@smatteo.pv.it
  organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
– sequence: 15
  givenname: Fausto
  surname: Baldanti
  fullname: Baldanti, Fausto
  organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
BookMark eNp9Uk2P0zAQjdAi9gP-ACcfuaT4OwlCSKtqgUorkNgVV8uxJ1uX1C62U9Q_yO_C2VagvXDyaGbeezPjd1md-eChql4TvCCYyLebhds4u6CYkgVuFhizZ9UFaZu2ZoKQsxJTTOquIfS8ukxpgzHmUrYvqnPGKaeNZBfV75U3zoI3gMKA7q6_3dXL8L2myPkBTHbBlwitQY95jYyOgH6F-ANiQkMMW_QlxLyG6NEq6_GAep3AooLRPrs-2ANKWecpvUNuu508oF0M-UT7iE9ggrc6Hv7p1egaRcgxpN2c2JfB-gRxr-eiHssQCeqCKh3jWNRSnuzhZfV80GOCV6f3qrr_eHO__Fzffv20Wl7f1oZ3ba7bRutGdLSnfJB9bzHuQJvBWCObVoieN0MPXBBJLQjZGUxa6AhrW2GE1IZdVasjrQ16o3bRbcvoKminHhMhPigdszMjqA73EhjBgpKWd4x3wPqOYM46JgbMh8L14ci1m_otWANlIz0-IX1a8W6tHsJetVRiIVgheHMiiOHnBCmrrUsGxlF7CFNSVAhMJSGcllZ6bDXlrCnC8FeGYDV7SW3U7CU1e0nhRhUvFdD7IwjKQfcOokrGzU6xLpafKSu7_8H_ADaz14g
CitedBy_id crossref_primary_10_3390_v13112261
crossref_primary_10_1371_journal_pone_0297901
crossref_primary_10_3390_microorganisms10061250
crossref_primary_10_2139_ssrn_3944582
crossref_primary_10_1186_s12916_022_02286_4
crossref_primary_10_3390_ijerph20021182
crossref_primary_10_1016_j_ijid_2022_06_028
crossref_primary_10_3390_healthcare10050896
crossref_primary_10_3390_ijms24108746
crossref_primary_10_1038_s41375_022_01578_1
crossref_primary_10_3390_ijerph19042282
crossref_primary_10_1038_s41467_021_26154_6
crossref_primary_10_12968_ijtr_2021_0201
crossref_primary_10_3389_fimmu_2021_786554
crossref_primary_10_2139_ssrn_3987537
crossref_primary_10_1001_jamanetworkopen_2022_1313
crossref_primary_10_3934_mbe_2022216
Cites_doi 10.1016/j.immuni.2020.04.023
10.1016/S0140-6736(21)00675-9
10.1056/NEJMoa2035389
10.1056/NEJMoa2034545
10.2807/1560-7917.ES.2020.25.24.2001031
10.1080/22221751.2021.1872352
10.1016/j.cell.2020.05.015
10.1093/infdis/jiaa659
10.1016/S1473-3099(20)30764-7
10.1016/S0140-6736(20)32661-1
ContentType Journal Article
Copyright 2021 The Author(s)
2021 The Author(s) 2021
Copyright_xml – notice: 2021 The Author(s)
– notice: 2021 The Author(s) 2021
DBID 6I.
AAFTH
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1016/j.ijid.2021.07.003
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1878-3511
EndPage 202
ExternalDocumentID oai_doaj_org_article_90b6e310521849349e3b91043935f04f
10_1016_j_ijid_2021_07_003
S1201971221005580
GroupedDBID ---
--K
.1-
.FO
.~1
0R~
0SF
1B1
1P~
1~.
1~5
29J
3O-
3V.
4.4
457
4G.
53G
5GY
5VS
6I.
7-5
71M
7X7
88E
8C1
8FI
8FJ
8FQ
8R4
8R5
AACTN
AAEDW
AAFTH
AAIKJ
AALRI
AAQFI
AAQXK
AARKO
AAXUO
ABBQC
ABFRF
ABMAC
ABUWG
ABVKL
ACGFO
ADBBV
ADEZE
ADMUD
AEFWE
AEKER
AENEX
AEVXI
AEXQZ
AFCTW
AFKRA
AFRHN
AFTJW
AGEKW
AGHFR
AGYEJ
AHMBA
AITUG
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
BAWUL
BCNDV
BENPR
BPHCQ
BR6
BVXVI
CCPQU
CS3
DIK
DU5
DWQXO
E3Z
EBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FNPLU
FYUFA
G-Q
GBLVA
GROUPED_DOAJ
GX1
HMCUK
HVGLF
HZ~
IHE
IXB
J1W
KQ8
M1P
M3C
M3G
M41
MO0
N9A
NCXOZ
O-L
O9-
OD-
OK1
OO.
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
PSQYO
Q2X
Q38
QTD
R2-
RIG
ROL
RPZ
RWL
RXW
SDF
SDG
SEL
SES
SEW
SSZ
TAE
UKHRP
UNMZH
Z5R
AAYXX
ADVLN
AFJKZ
AKRWK
ALIPV
CITATION
7X8
5PM
ID FETCH-LOGICAL-c498t-87aa7592b24f6bbd009eacfcdc67855b47fbe45162de569c018e913885c56ac3
IEDL.DBID ABVKL
ISSN 1201-9712
IngestDate Tue Oct 22 15:07:00 EDT 2024
Tue Sep 17 21:17:21 EDT 2024
Fri Oct 25 10:40:21 EDT 2024
Thu Sep 26 15:23:48 EDT 2024
Fri Feb 23 02:37:08 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords SARS-CoV-2 infection
neutralizing antibody
immune protection
secondary infection
Language English
License This is an open access article under the CC BY-NC-ND license.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c498t-87aa7592b24f6bbd009eacfcdc67855b47fbe45162de569c018e913885c56ac3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Equally contributed
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S1201971221005580
PMID 34242763
PQID 2550261142
PQPubID 23479
PageCount 4
ParticipantIDs doaj_primary_oai_doaj_org_article_90b6e310521849349e3b91043935f04f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8260553
proquest_miscellaneous_2550261142
crossref_primary_10_1016_j_ijid_2021_07_003
elsevier_sciencedirect_doi_10_1016_j_ijid_2021_07_003
PublicationCentury 2000
PublicationDate August 2021
2021-08-00
20210801
2021-08-01
PublicationDateYYYYMMDD 2021-08-01
PublicationDate_xml – month: 08
  year: 2021
  text: August 2021
PublicationDecade 2020
PublicationTitle International journal of infectious diseases
PublicationYear 2021
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Kim, Kim, Park, Kim, Yu, Chang (bib0005) 2021; 10
Ni, Ye, Cheng, Feng, Deng, Zhao (bib0008) 2020; 52
Van Elslande, Vermeersch, Vandervoort, Wawina-Bokalanga, Vanmechelen, Wollants (bib0013) 2020
Voysey, Clemens, Madhi, Weckx, Folegatti, Aley (bib0014) 2021; 397
Hall, Foulkes, Charlett, Atti, Monk, Simmons (bib0004) 2021; 397
Percivalle, Cambiè, Cassaniti, Nepita, Maserati, Ferrari (bib0010) 2020; 25
O Murchu, Byrne, Carty, De Gascun, Keogan, O'Neill (bib0009) 2021
Tillett, Sevinsky, Hartley, Kerwin, Crawford, Gorzalski (bib0011) 2021; 21
Baden, El Sahly, Essink, Kotloff, Frey, Novak (bib0001) 2021; 384
Lumley, O'Donnell, Stoesser, Matthews, Howarth, Hatch (bib0006) 2021; 384
To, Hung, Ip, Chu, Chan, Tam (bib0012) 2020
Muecksch, Wise, Batchelor, Squires, Semple, Richardson (bib0007) 2021; 223
Grifoni, Weiskopf, Ramirez, Mateus, Dan, Moderbacher (bib0003) 2020; 181
(bib0002) 2021
Kim (10.1016/j.ijid.2021.07.003_bib0005) 2021; 10
To (10.1016/j.ijid.2021.07.003_bib0012) 2020
Ni (10.1016/j.ijid.2021.07.003_bib0008) 2020; 52
Percivalle (10.1016/j.ijid.2021.07.003_bib0010) 2020; 25
Baden (10.1016/j.ijid.2021.07.003_bib0001) 2021; 384
(10.1016/j.ijid.2021.07.003_bib0002) 2021
Muecksch (10.1016/j.ijid.2021.07.003_bib0007) 2021; 223
O Murchu (10.1016/j.ijid.2021.07.003_bib0009) 2021
Tillett (10.1016/j.ijid.2021.07.003_bib0011) 2021; 21
Grifoni (10.1016/j.ijid.2021.07.003_bib0003) 2020; 181
Van Elslande (10.1016/j.ijid.2021.07.003_bib0013) 2020
Voysey (10.1016/j.ijid.2021.07.003_bib0014) 2021; 397
Lumley (10.1016/j.ijid.2021.07.003_bib0006) 2021; 384
Hall (10.1016/j.ijid.2021.07.003_bib0004) 2021; 397
References_xml – year: 2020
  ident: bib0013
  article-title: Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain
  publication-title: Clin Infect Dis
  contributor:
    fullname: Wollants
– volume: 384
  start-page: 403
  year: 2021
  end-page: 416
  ident: bib0001
  article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
  publication-title: N Engl J Med
  contributor:
    fullname: Novak
– volume: 384
  start-page: 533
  year: 2021
  end-page: 540
  ident: bib0006
  article-title: Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
  publication-title: N Engl J Med
  contributor:
    fullname: Hatch
– volume: 223
  start-page: 389
  year: 2021
  end-page: 398
  ident: bib0007
  article-title: Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
  publication-title: J Infect Dis
  contributor:
    fullname: Richardson
– volume: 21
  start-page: 52
  year: 2021
  end-page: 58
  ident: bib0011
  article-title: Genomic evidence for reinfection with SARS-CoV-2: a case study
  publication-title: Lancet Infect Dis
  contributor:
    fullname: Gorzalski
– volume: 10
  start-page: 152
  year: 2021
  end-page: 160
  ident: bib0005
  article-title: Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
  publication-title: Emerg Microbes Infect
  contributor:
    fullname: Chang
– start-page: e2260
  year: 2021
  ident: bib0009
  article-title: Quantifying the risk of SARS-CoV-2 reinfection over time
  publication-title: Rev Med Virol
  contributor:
    fullname: O'Neill
– volume: 397
  start-page: 1459
  year: 2021
  end-page: 1469
  ident: bib0004
  article-title: SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative healthcare workers in England: a large, multicentre, prospective cohort study (SIREN)
  publication-title: Lancet
  contributor:
    fullname: Simmons
– volume: 52
  year: 2020
  ident: bib0008
  article-title: Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
  publication-title: Immunity
  contributor:
    fullname: Zhao
– year: 2021
  ident: bib0002
  article-title: Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. April 08th, 2021
– volume: 181
  year: 2020
  ident: bib0003
  article-title: Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
  publication-title: Cell
  contributor:
    fullname: Moderbacher
– volume: 25
  year: 2020
  ident: bib0010
  article-title: Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as of April 06th, 2020
  publication-title: Euro Surveill
  contributor:
    fullname: Ferrari
– year: 2020
  ident: bib0012
  article-title: COVID-19 reinfection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole-genome sequencing
  publication-title: Clin Infect Dis
  contributor:
    fullname: Tam
– volume: 397
  start-page: 99
  year: 2021
  end-page: 111
  ident: bib0014
  article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  publication-title: Lancet
  contributor:
    fullname: Aley
– volume: 52
  year: 2020
  ident: 10.1016/j.ijid.2021.07.003_bib0008
  article-title: Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.04.023
  contributor:
    fullname: Ni
– volume: 397
  start-page: 1459
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0004
  article-title: SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative healthcare workers in England: a large, multicentre, prospective cohort study (SIREN)
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00675-9
  contributor:
    fullname: Hall
– year: 2020
  ident: 10.1016/j.ijid.2021.07.003_bib0013
  article-title: Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain
  publication-title: Clin Infect Dis
  contributor:
    fullname: Van Elslande
– volume: 384
  start-page: 403
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0001
  article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2035389
  contributor:
    fullname: Baden
– volume: 384
  start-page: 533
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0006
  article-title: Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2034545
  contributor:
    fullname: Lumley
– volume: 25
  year: 2020
  ident: 10.1016/j.ijid.2021.07.003_bib0010
  article-title: Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as of April 06th, 2020
  publication-title: Euro Surveill
  doi: 10.2807/1560-7917.ES.2020.25.24.2001031
  contributor:
    fullname: Percivalle
– volume: 10
  start-page: 152
  issue: 1
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0005
  article-title: Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
  publication-title: Emerg Microbes Infect
  doi: 10.1080/22221751.2021.1872352
  contributor:
    fullname: Kim
– volume: 181
  year: 2020
  ident: 10.1016/j.ijid.2021.07.003_bib0003
  article-title: Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
  publication-title: Cell
  doi: 10.1016/j.cell.2020.05.015
  contributor:
    fullname: Grifoni
– volume: 223
  start-page: 389
  issue: 3
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0007
  article-title: Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiaa659
  contributor:
    fullname: Muecksch
– year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0002
– volume: 21
  start-page: 52
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0011
  article-title: Genomic evidence for reinfection with SARS-CoV-2: a case study
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(20)30764-7
  contributor:
    fullname: Tillett
– year: 2020
  ident: 10.1016/j.ijid.2021.07.003_bib0012
  article-title: COVID-19 reinfection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole-genome sequencing
  publication-title: Clin Infect Dis
  contributor:
    fullname: To
– start-page: e2260
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0009
  article-title: Quantifying the risk of SARS-CoV-2 reinfection over time
  publication-title: Rev Med Virol
  contributor:
    fullname: O Murchu
– volume: 397
  start-page: 99
  year: 2021
  ident: 10.1016/j.ijid.2021.07.003_bib0014
  article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32661-1
  contributor:
    fullname: Voysey
SSID ssj0004668
Score 2.4287145
Snippet •Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing...
OBJECTIVEThe protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was...
• Immunity from natural SARS-CoV-2 infection is protective in healthcare workers • Secondary infection is associated with low or absent serum neutralizing...
Objective: The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was...
SourceID doaj
pubmedcentral
proquest
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Publisher
StartPage 199
SubjectTerms immune protection
neutralizing antibody
SARS-CoV-2 infection
secondary infection
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUSQlBALI9qkLghi8Sxk7i3pWpVkMqBFtSbFTuOSIUSlN097B_kd3XGTpbNpVy4RXnZyUzmEX_fDGPvZaVyV9QZlwo1WDYu4TZzBXeJFr6QOstD077Lr_nFd_nlRt3stfoiTFgsDxxf3Eed2NxjDKIoF9GZ1D6z6OIkUUqbRDbB-iZ6SqZ2jMhIgkP3xnWRipEuE5Fd7W1LNUJFGsp2Tu2yRpcUKvfPPNNe5DnHTe45ovMn7PEYQcIyzvwpe-C7I3Z4Oa6RH7FH8U8cRILRM_YHTUDsHAp9A1fLb1f8tP_BBUw4rA63IPIhgYBgQFgtjAqBqCcQFnb80MFnDNO3QF6vBrwGJdLavt4CUZI2qxNoiWniYSz8QLcN168o466rYft3PA5LGPx66CeaJ_R293MYH83hGHzE0P_C0UIJ3Ofs-vzs-vSCj90buJO6XKOZrapCaWGFbHJrawzm0Mg3rnboH5WysmispzbBovYq1y5JS6_TrCyVU3nlshfsoOs7_5KBdGhkFB6sK0z_pNVljqrn0RwJbctKLdiHSX7md6zRYSbw2q0haRuStkloqT1bsE8k4t2ZVF877ECtM6PWmX9p3YKpSUHMGKrEEARv1d47-LtJmwx-x7Q4U3W-36wMpnaUDqdSLFgxU7PZTOdHuvZnqAheUlaqslf_49Fes4c04QhyfMMO1sPGv8XAa22Pwzd2ByyVLDg
  priority: 102
  providerName: Directory of Open Access Journals
Title Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study
URI https://dx.doi.org/10.1016/j.ijid.2021.07.003
https://search.proquest.com/docview/2550261142
https://pubmed.ncbi.nlm.nih.gov/PMC8260553
https://doaj.org/article/90b6e310521849349e3b91043935f04f
Volume 109
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKKyEkhEoBsTxWRuKGwuZhJzG33VWrllIk2FLtzYodB1KhpMruHvbCz-N3MWM77ebSA5do83DszYznYc83Q8h7VvBUZ2USMA4czCodBirRWaBDEZuMiSS1RfsuvqanP9jnJV_ukXmPhcGwSi_7nUy30tpfmfivObmp68kiAt0lsigGpyXkPAe__SAG6xdm58F0dnX-ZQce6RBx8HyADTx2xoV51dc1JgyNI5vDs6-d5fWTTeM_UFM7ZugwiHJHK50ckifenKRTN-KnZM80R-Thhd8wPyKP3bIcdWijZ-QvyANXRpS2FV1Mvy-CeXsVxLQPymrgF3XgSIpRYRQDt8BEpIhDoXaXx3QNPQObfUtRBZYU2gB5atWWW4r4pM3qE60RdmKozwKBr7XtV-h-l0W3vesvoFPamXXX9phP2qrblWL4axr6CHxA_W_ozebDfU4uT44v56eBL-UQaCbyNcjcosi4iFXMqlSpEiw7kPiVLjUoS84VyyplsGZwXBqeCh1GuRFRkudc87TQyQuy37SNeUko0yBxONwsC_AFmRJ5CnxoQDbFQuUFH5EPPf3kjUvYIftItmuJ1JZIbRnivnsyIjMk8e2TmGzbXmi7n9JzmxShSg2YwRzdYZEwYRIFVhZDVHMVsmpEeM8gcsC78Kr63s7f9dwkYVLjTk3RmHazkuDnoW8csXhEsgGbDUY6vNPUv2x68BxdVJ68-s9RvSaP8MwFOb4h--tuY96C4bVWY_Lg459o7KfX2C5fwPFsOYPj-bf8H_BTM-c
link.rule.ids 230,315,783,787,867,888,2109,3513,4509,27581,27936,27937,45597,45675,45886
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgESQlBALE8jcUOmedhJzG1ZUW2h2wO7oN6s2HFKKpRU2d3DXvh5_C5mbKdsLhy4RbEdO5nJPOz5Zgh5y0uRmbxKGRfAwbw2EdOpyZmJZGJzLtPMFe1bnGfzb_zzhbg4ILMBC4NhlUH2e5nupHW4cxy-5vF10xwvY9BdMo8TcFoiIQrw229xtI-Bqd__ivfAkR4PB70Zdg_IGR_k1Vw1mC40iV0Gz6FyVtBOLon_SEntGaHjEMo9nXTygNwPxiSd-vU-JAe2PSK3F-G4_Ijc85ty1GONHpHfIA18EVHa1XQ5_bpks-47S-gQktXCFfXQSIoxYRTDtsBApIhCoe6Mx_YtPQWLfUdRAVYUxgBxGt1VO4ropO36A20QdGJpyAGBj3Xj1-h8V2W_-zsfo1Pa203fDYhP2umbfWJ4NQNzsBBO_xNmc9lwH5PVyafVbM5CIQdmuCw2IHHLMhcy0QmvM60rsOtA3temMqAqhdA8r7XFisFJZUUmTRQXVsZpUQgjstKkT8hh27X2KaHcgLwR0FiV4AlyLYsMuNCCZEqkLkoxIe8G-qlrn65DDXFsVwqprZDaKsJT93RCPiKJb3piqm13o-svVeA1JSOdWTCCBTrDMuXSphpsLI6Y5jri9YSIgUHUiHPhUc0_J38zcJOCXxrPacrWdtu1Ai8PPeOYJxOSj9hstNJxS9v8cMnBC3RQRfrsP1f1mtyZrxZn6uz0_MtzchdbfLjjC3K46bf2JZhgG_3K_WJ_ABQ9McI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+of+SARS-CoV-2+infection+in+health+care+workers+from+Northern+Italy+based+on+antibody+status%3A+immune+protection+from+secondary+infection-+A+retrospective+observational+case-controlled+study&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Rovida%2C+Francesca&rft.au=Cassaniti%2C+Irene&rft.au=Percivalle%2C+Elena&rft.au=Sarasini%2C+Antonella&rft.date=2021-08-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.eissn=1878-3511&rft.volume=109&rft.spage=199&rft.epage=202&rft_id=info:doi/10.1016%2Fj.ijid.2021.07.003&rft.externalDocID=S1201971221005580
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon